IndustryCompany release

Travere's FILSPARI U.S. sales reach $200.2m in Q3 as licensing charge widens loss

🇺🇸 Travere Therapeutics, Inc. (TVTX) · Mon 02 Nov 2026

Travere Therapeutics reports 120% growth in U.S. FILSPARI sales for the third quarter, while a $113.1m IPR&D expense drives a $52.3m net loss.

Travere Therapeutics reported its third-quarter 2026 results on 2 November, with U.S. net sales of FILSPARI (sparsentan) reaching $200.2m. The company said this was a 120% increase. The product is marketed in the U.S. for IgA nephropathy and focal segmental glomerulosclerosis (FSGS).

The company also received 1,932 new patient start forms in the quarter, a measure of how many patients are being initiated on treatment.

Travere posted a net loss of $52.3m for the period. The company attributed this to a $113.1m in-process research and development (IPR&D) expense linked to its licence of civorebrutinib from Everest Medicines.

Looking ahead, Travere expects topline Phase 3 HARMONY results for pegtibatinase in classical homocystinuria in the second half of 2027. It also plans to file a U.S. investigational new drug (IND) application for civorebrutinib by the end of this year.

What it means for your team

  • Market-access teams can note that FILSPARI's U.S. uptake in IgA nephropathy and FSGS is strong, with 1,932 new patient start forms received in the quarter.
  • Regulatory teams should watch for the planned U.S. IND for civorebrutinib by year-end, the first formal U.S. step for the in-licensed asset.
  • The pegtibatinase HARMONY Phase 3 readout in classical homocystinuria is guided for the second half of 2027, setting the timeline for any later regulatory submission.

Company's press release (SEC filing): Travere Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Travere Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →